SironRX Raises $3.4M for SDF-1 Wound Therapy Trials
By Marie Powers
Wednesday, August 17, 2011
SironRX Therapeutics Inc., a regenerative medicine spinoff from the Cleveland Clinic that is developing a topical therapy to accelerate dermal and bone healing and decrease scar formation, closed a $3.4 million Series A investment. The company plans to use the funds to begin clinical trials of its wound therapy technology and to build its senior management and clinical team, according to Rahul Aras, the company's co-founder, president and CEO.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.